Suven Life Sciences Ltd, on March 12, 2008 has announced that the Company has signed a second agreement with Eli Lilly and company, a US based global pharmaceutical company to collaborate on the pre-clinical research of molecules in the therapeutic area of central nervous system disorders (CNS).

As per the collaboration agreement, Suven will be responsible for discovery activities related to the identification and selection of clinical candidates in the area of CNS, in close association with Lilly.

Under the terms of the collaboration agreement, Suven will receive research funding and as well as potential discovery and development milestone payments in the range of $ 19 million to $ 23 million per candidate and potential royalties on net sales of any products that may be successfully commercialized from the collaboration.

“We are very pleased and excited that Lilly has continued collaborate with us in the CNS arena, thus showing the confidence in Suven’s drug discovery capabilities.” says Dr. Ramakrishna Nirogi, Vice President, Drug Discovery of Suven life Sciences.

“We believe our collaborations with Lilly validate Suven’s leadership position in CNS drug discovery” says Venkat Jasti, CEO of Suven Life Sciences. “This Collaboration leverages Suven’s small molecule drug discovery expertise with Lilly?S expertise and leadership position in CNS, with the goal of creating innovative products for unmet medical needs”.